A.n.n.

Started a BRAF Colorectal Cancer Public Library group on Facebook. So many significant trials, research findings, changes to NCCN guidelines, etc. in the last 2 years. Gathering high level research/interviews into 1 place seems wise and useful. #BRAFCRC facebook.com/groups/2084906…

#FollowFriday Meet Ignacio Garrido-Laguna, MD, PhD (@GarridoLagunaMD), chair of Moffitt’s Department of Early Therapeutics Development. He specializes in GI cancers, including pancreatic, colorectal and cholangiocarcinoma, with expertise in phase 1 clinical trials. In this role, he advances early access to innovative therapies for patients. #MoffittAmbassadors

Attending #AACR26? Timothy A. Yap, Editor-in-Chief, will moderate an interactive Professional Development Session on how to navigate the publishing process. Monday, April 20, 5:30-7:00 p.m. Register: brnw.ch/21x0SZg

#KRASatAACR26 1330 - Targeting Aurora kinase A for potentiating colorectal cancer to KRAS targeted therapy abstractsonline.com/pp8/?fbclid=Iw… April 19th @AACR #KRAS #AACR26

#KRASatAACR26 LB407 / 7 - Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC) April 21 MiniSymposium: Late-Breaking Research abstractsonline.com/pp8/?fbclid=Iw… @AACR @CentralParkWMD @aparna1024 #KRAS #AACR26

💉 The Day Immunotherapy Went Off-Patent Nivolumab changed cancer care. Five-year survival in advanced melanoma jumped from 10–15% to nearly 50%. Lung, kidney, and other cancers saw outcomes once thought impossible. Now its patent is expiring. Biosimilars are arriving, prices may fall, and access could widen especially in regions long left behind. A quiet milestone for headlines. A seismic shift for patients. Science succeeded. The next challenge: making survival global. 👉 Read the full CancerWorld article by Dr. Amalya Sargsyan here: cancerworld.net/the-day-immuno… @oncodaily | @amalsargsyan #Immunotherapy #CancerCare #Oncology #Biosimilars #PrecisionMedicine #HealthcareEquity #CancerResearch #PatientAccess #MedicalInnovation

Get the latest on #colorectalcancer stats, screening guidelines, & new options during our FREE webinar March 25 featuring gastro Dr. Swati Patel (@swatigp) & #rectalcancer survivor Jessica Acosta. Register now: fightcolorectalcancer.org/event/colorect…

That would be the dream....

fishing or phishing?

Applications are now open for the SCI Community Impact Research Grants aimed at addressing #CancerDisparities. I encourage you to apply and make a difference. brnw.ch/21x0QBz

"We hope to convert advanced colorectal cancer into a manageable disease." #ICYMI: MSK physician-scientist @KarunaMDPhD and colleagues were awarded a @CancerGrand grant — a prestigious global initiative providing up to $25 million over five years to tackle some of the toughest problems in cancer research. Learn more: bit.ly/4d1GX4p

Dr. Nora Disis and Dr. Kiran Dhillon of the UW Cancer Vaccine Institute have been invited to the 2026 XPRIZE Global Visioneering Brain Trust (Health). They’ll help shape bold solutions to accelerate innovation and advance transformative cancer prevention and treatment. #UWCVI

$ANL -3.96% today Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations More Info: pryzm.ozmosi.com/product/37014

Adding pelareorep to standard-of-care therapy in patients with KRAS-mutated microsatellite-stable CRC exhibited an ORR of 33%. hubs.li/Q03YTxYF0 #crcsm #Oncology #Cancer

FDA Grants Fast Track Designation to Pelareorep Plus Bevacizumab/FOLFIRI in Second-Line KRAS-Mutant mCRC #oncology #medtwitter #CRC hubs.li/Q041Q-5c0

🔎 The #FDA has fast-tracked pelareorep with bevacizumab and FOLFIRI for KRAS-mutant MSS metastatic #ColorectalCancer, after standout response and survival signals. hubs.li/Q041QLxZ0

Pelareorep Earns FDA Fast Track for Second-Line KRAS-Mutant Metastatic CRC Targeted Oncology news coverage targetedonc.com/view/pelareore… ESMO 2018 poster d1io3yog0oux5.cloudfront.net/_35c06e7e5f847… New members of GI Tumor Scientific Advisory Board oncolyticsbiotech.com/press_releases… @VanMorrisMD

Pelareorep with bevacizumab and FOLFIRI has earned fast track designation from the FDA for MSS metastatic CRC harboring KRAS mutations. hubs.li/Q04297Vl0 #crcsm #Oncology #Cancer

Pelareorep has received @US_FDA fast track designation alongside SOC bevacizumab/FOLFIRI in 2nd line KRAS-mutant, MSS mCRC based on data from the phase 1 REO 022 trial. #crcsm #oncology Read more about this regulatory decision 👇📰: onclive.com/view/fda-grant…

🧬 @Oncolytics launches Phase 2 REO-033 for pelareorep in metastatic colorectal cancer. 📊 Prior data • 27 mo OS vs ~11 mo SOC • 33% response vs ~10% oncodaily.com/techology/reo-… #Biotech #ClinicalTrials #Oncology #Cancer #OncoDaily

@BiachiTiago @MoffittNews Will post in minimal Residual Disease group on FB 41 locations!! 👌 #mrd NCT07023289 ClinicalTrials.gov share.google/EVXHWztV0ixw44…

Pts with stage III-IV(resected) #colorectalcancer with NED on the scans and positive ctDNA remain a challenge in clinic. This trial below (NCT07023289) is now open at @MoffittNews and randomizes to close surveillance vs a cMET ADC. Feel free to reach out to refer pts here or at GIClinicalTrialReferrals@moffitt.org #clinicalresearcheverywhere @FightCRC @CCAlliance